Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects

NCT04829123 is registered in ClinicalTrials.gov with Dongguan HEC Biopharmaceutical R&D Co., Ltd. as lead sponsor.

NCT NCT04829123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04829123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
Lead sponsor
Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 14, 2021
Completion date
March 2, 2022
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis